2019
DOI: 10.1016/j.pharep.2018.10.013
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(31 citation statements)
references
References 26 publications
1
30
0
Order By: Relevance
“…In a recent study on a murine model, metformin treatment reduced markers of inflammation and lipoperoxidation in the liver and, at the same time, attenuated the loss of tight junction proteins in the small intestine, resulting in a decrease in the translocation of bacterial endotoxins in portal plasma and therefore in a protective effect upon NAFLD onset [35]. Furthermore, in a recent study on 42 NAFLD non-diabetic patients, significant reductions in hepatic steatosis and fibrosis were shown, which were evaluated by controlled attenuation parameter (CAP) and liver stiffness after five months of treatment with metformin and diet, compared to patients treated with diet alone [36]. Contrarily, a meta-analysis of 17 randomized controlled trials (RCTs) showed that 6–12 months of metformin plus lifestyle intervention did not improve liver histology or aminotransferases among NAFLD diabetic patients, compared with lifestyle intervention alone [37].…”
Section: Resultsmentioning
confidence: 99%
“…In a recent study on a murine model, metformin treatment reduced markers of inflammation and lipoperoxidation in the liver and, at the same time, attenuated the loss of tight junction proteins in the small intestine, resulting in a decrease in the translocation of bacterial endotoxins in portal plasma and therefore in a protective effect upon NAFLD onset [35]. Furthermore, in a recent study on 42 NAFLD non-diabetic patients, significant reductions in hepatic steatosis and fibrosis were shown, which were evaluated by controlled attenuation parameter (CAP) and liver stiffness after five months of treatment with metformin and diet, compared to patients treated with diet alone [36]. Contrarily, a meta-analysis of 17 randomized controlled trials (RCTs) showed that 6–12 months of metformin plus lifestyle intervention did not improve liver histology or aminotransferases among NAFLD diabetic patients, compared with lifestyle intervention alone [37].…”
Section: Resultsmentioning
confidence: 99%
“…To the best of our knowledge, our study was the first study to evaluate the long-term treatment responses of NAFLD to bariatric surgery using TE as a monitoring tool. In the literature, TE had been tested on the roles of monitoring disease progression and response to treatment of NAFLD [21][22][23][24][25] . Suzuki et al reported the changes of LSM over 4 years in 36 patients without paired liver biopsies for monitoring disease progression of NAFLD 21 .…”
Section: Discussionmentioning
confidence: 99%
“…In addition to the studies described above, multiple openlabel studies compared metformin to a thiazolidinedione (24,49,70) or to lifestyle alone (12,23,25,29,47,54,64,69) with regard to improvements in liver fat or inflammation measured by MRI/MRS, CT, US, fibroscan, or biopsy. The three studies directly comparing metformin to a TZD all showed benefit of the TZD to reduce liver fat (24,49,70), whereas only one showed a significant effect of metformin, albeit smaller in magnitude than the effect of TZD (70).…”
Section: Metforminmentioning
confidence: 99%
“…The three studies directly comparing metformin to a TZD all showed benefit of the TZD to reduce liver fat (24,49,70), whereas only one showed a significant effect of metformin, albeit smaller in magnitude than the effect of TZD (70). Of 7 studies comparing effects of metformin vs. lifestyle on liver fat content (12,23,25,29,47,54,64), six showed positive effects of metformin to lower liver fat (12,23,25,29,47,54), but, in all of these studies, metformin either was not clearly superior to lifestyle or was not directly compared to lifestyle. Similarly, in the 5 studies investigating changes in hepatocellular inflammation or fibrosis (12,25,29,64,69), metformin showed trends to modestly improve inflammation and/or fibrosis in 4 of them (12,25,64,69), but none definitely demonstrated an effect that was superior to lifestyle alone.…”
Section: Metforminmentioning
confidence: 99%
See 1 more Smart Citation